The Manufacturers Life Insurance Company raised its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 38.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,621 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,167 shares during the quarter. The Manufacturers Life Insurance Company owned 0.06% of Collegium Pharmaceutical worth $233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. American International Group Inc. lifted its position in Collegium Pharmaceutical by 27.8% during the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,163 shares during the last quarter. Voya Investment Management LLC bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $125,000. Credit Suisse AG lifted its position in Collegium Pharmaceutical by 9.4% during the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after purchasing an additional 1,173 shares during the last quarter. UBS Group AG lifted its position in Collegium Pharmaceutical by 283.2% during the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 10,174 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares during the last quarter. Institutional investors and hedge funds own 79.98% of the company’s stock.

Shares of Collegium Pharmaceutical, Inc. (COLL) opened at $17.70 on Friday. Collegium Pharmaceutical, Inc. has a 1-year low of $7.37 and a 1-year high of $20.92.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.28. The firm had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.13) EPS. analysts anticipate that Collegium Pharmaceutical, Inc. will post -2.56 earnings per share for the current fiscal year.

In other news, CTO Alison B. Fleming sold 4,029 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the completion of the sale, the chief technology officer now directly owns 28,513 shares in the company, valued at approximately $484,721. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 58,630 shares of company stock valued at $924,360. Company insiders own 25.76% of the company’s stock.

Several equities research analysts have issued reports on COLL shares. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, November 13th. Jefferies Group lifted their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC lifted their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. They noted that the move was a valuation call. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $14.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, September 8th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.50.

WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-shares-bought-by-the-manufacturers-life-insurance-company/1753267.html.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.